

# Ghrelin receptor agonists - Pipeline Insight, 2022

<https://marketpublishers.com/r/GE9FCD94F845EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: GE9FCD94F845EN

## Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Ghrelin Receptor Agonist - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Ghrelin Receptor Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Ghrelin Receptor Agonist Understanding

#### Ghrelin Receptor Agonist: Overview

Ghrelin is a hormone produced by specific cells in the stomach. It exerts its action by binding to receptors in the hypothalamus involved in the regulation of food intake. Ghrelin causes an increase in the pituitary secretion of growth hormone (GH). Drugs that bind and activate the ghrelin receptor have been explored for their effect on appetite, weight gain, frailty, cachexia, inflammation and gut motility. Ghrelin exerts its effects through a specific G-protein-coupled receptor called the growth hormone secretagogue receptor 1a (GHSR1a). Another GHSR cDNA is produced by alternative splicing which produces a COOH-terminal truncated form (GHSR1b) that is pharmacologically inactive. The GHSR1a is expressed in several areas of the hypothalamus associated with feeding behaviour, including the arcuate and

ventromedial nuclei. GHS?R1a is also found in the pituitary gland, and other organs such as bone, heart, lung, liver, kidney, pancreas and immune cells.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Ghrelin Receptor Agonist R&D. The therapies under development are focused on novel approaches for Ghrelin Receptor Agonist.

## Ghrelin Receptor Agonist Emerging Drugs Chapters

This segment of the Ghrelin Receptor Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Ghrelin Receptor Agonist Emerging Drugs

### Anamorelin HCl: Helsinn Therapeutics/Ono Pharmaceutical

Anamorelin HCl is an orally-active selective ghrelin receptor agonist which has shown anabolic and appetite-stimulating effects. Several randomized, double-blind, clinical trials in cancer patients have shown that anamorelin HCL is safe, efficacious and increases lean body mass, bodyweight, and appetite. Investigators propose to test anamorelin HCL administered with chemotherapy in the first-line treatment of locally advanced unresectable and metastatic pancreatic cancer. Its Phase II trial is expected to start in August 2021.

Further product details are provided in the report.....

## Ghrelin Receptor Agonist: Therapeutic Assessment

This segment of the report provides insights about the different Ghrelin Receptor Agonist drugs segregated based on following parameters that define the scope of the report, such as:

## Major Players working on Ghrelin Receptor Agonist

There are approx. 5+ key companies which are developing the Ghrelin Receptor Agonist. The companies which have their Ghrelin Receptor Agonist drug candidates in the most advanced stage, i.e. Phase II include, Helsinn Therapeutics/Ono Pharmaceutical.

## Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Ghrelin Receptor Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ghrelin Receptor Agonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Ghrelin Receptor Agonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ghrelin Receptor Agonist drugs.

## Ghrelin Receptor Agonist Report Insights

Ghrelin Receptor Agonist Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## Ghrelin Receptor Agonist Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Scenario and Emerging Therapies:

How many companies are developing Ghrelin Receptor Agonist drugs?

How many Ghrelin Receptor Agonist drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Ghrelin Receptor Agonist?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ghrelin Receptor Agonist therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Ghrelin Receptor Agonist and their status?

What are the key designations that have been granted to the emerging drugs?

### Key Players

Helsinn Therapeutics/Ono Pharmaceutical

AEterna Zentaris

### Key Products

Anamorelin HCl

Macimorelin

## Contents

Introduction

Executive Summary

Ghrelin Receptor Agonist: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Ghrelin Receptor Agonist – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Ghrelin Receptor Agonist companies' collaborations, Licensing, Acquisition -Deal

Value Trends

Ghrelin Receptor Agonist Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Anamorelin HCl: Helsinn Therapeutics/Ono Pharmaceutical

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Macimorelin: AEterna Zentaris

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Ghrelin Receptor Agonist Key Companies

Ghrelin Receptor Agonist Key Products

Ghrelin Receptor Agonist- Unmet Needs

Ghrelin Receptor Agonist- Market Drivers and Barriers

Ghrelin Receptor Agonist- Future Perspectives and Conclusion

Ghrelin Receptor Agonist Analyst Views

Ghrelin Receptor Agonist Key Companies

Appendix



## List Of Tables

### LIST OF TABLES

- Table 1 Total Products for Ghrelin Receptor Agonist
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Ghrelin Receptor Agonist
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Ghrelin receptor agonists - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/GE9FCD94F845EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE9FCD94F845EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970